ClinicalTrials.gg
CompletedNCT03382496EVIDENSUpdated May 25, 2022

Observational Study for Lung Cancer Patients Treated With Nivolumab

An observational study in Lung Cancer, sponsored by Bristol-Myers Squibb. Completed at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-05-25.

Sponsored by Bristol-Myers Squibb · Observational

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
1,462
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 40 studies in Lung Neoplasms by Bristol-Myers Squibb — 6 open to participants now, 9 under way, 2 of them phase 3. Lung Neoplasms · Bristol-Myers Squibb.

Started
2016
with 6 others
Observational
6 of 40
none open now
Registered
24th of 40
by date

Among the 40 studies in Lung Neoplasms by Bristol-Myers Squibb, this one is one of 7 that started in 2016, is one of 6 observational ones, and was the 24th registered.

Lung Neoplasms

5,427 studies on the registry are indexed under Lung Neoplasms; 1,345 are open to participants now.

Browse Lung Neoplasms studies →

Open to participants now

6 of the 40 studies in Lung Neoplasms by Bristol-Myers Squibb are open now, in 12 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

Who these studies take

Of the 995 Lung Neoplasms studies recruiting now, 684 (69%) set no upper age limit and 142 (14%) stop at 75 or younger; 45 take children under 18; 142 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 40 studies in Lung Neoplasms by Bristol-Myers Squibb, or all of them as a file.
02

Study summary

This study will describe the characteristics of patients initiating nivolumab treatment for lung cancer and their outcomes over 3 years in France

03

Conditions studied

  • Lung Cancer

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

This study aims to collect data for patients diagnosed with a lung cancer and initiating nivolumab in France

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female: 18 age at the time of nivolumab initiation
  • confirmed diagnosis of lung cancer
  • Patient initiating nivolumab :therapeutic decision to initiate nivolumab must be taken by the physician prior to enrolling a patient in the study

Exclusion criteria

Exclusion Criteria:

-Patient taking part in an interventional study for lung cancer treatment for which nivolumab is 1 of the drugs

Other protocol defined inclusion or exclusion criteria could apply

Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
1,462 participants (actual)
Patient registry
No

Groups and cohorts

  • Lung Cancer patients in France

    Lung Cancer patients treated by nivolumab in real life condition in France from October 2016 to October 2017

    Other: Non-Interventional

Interventions

  • OtherNon-Interventional

    Non-Interventional

This study also gives Nivolumab. No intervention listed here names it: that was found by reading the record.

06

What researchers measure

Primary outcomes

  1. Distribution of gender

    Time frame: At baseline

  2. Distribution of age

    Time frame: At baseline

  3. Distribution of line of therapy at nivolumab initiation

    Time frame: At baseline

  4. Distribution of ECOG PS

    Eastern Cooperative Oncology Group Performance Status (ECOG PS) A scale used to assess how a patient's disease is progressing, assess how the disease affects the daily living abilities of the patient, and determine appropriate treatment and prognosis

    Time frame: At baseline

  5. Distribution of patients working status at nivolumab initiation

    Time frame: At baseline

  6. QoL (EQ-5D) at nivolumab initiation

    Quality of Life (QoL) as assessed by European Quality of Life-5 Dimensions (EQ-5D) EQ-5D: the descriptive system consists of 5 dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression, each with 3 levels (eg, no problems, moderate problems, extreme problems)

    Time frame: At baseline

  7. Median time from initial diagnosis to nivolumab initiation

    Median time from initial diagnosis to nivolumab initiation (derived from date of initial diagnosis and date of first dose of nivolumab, assumed to be the date of D0 visit). Any lung cancer declaring more than 5 years after another cancer is defined as an initial diagnosis of lung cancer

    Time frame: At baseline

  8. Number of patients exposed to other lung cancer treatments

    Time frame: At baseline

  9. Distribution of current smokers, former smokers, and non-smokers at initial diagnosis

    Time frame: At baseline

  10. Distribution of cancer stage at initial diagnosis and at nivolumab initiation

    Time frame: At baseline

  11. Distribution of Lung cancer histology at initial diagnosis

    Time frame: At baseline

  12. Number of patients with untreated brain metastasis at nivolumab initiation

    Time frame: At baseline

  13. Number of patients with treated brain metastasis at nivolumab initiation

    Time frame: At baseline

  14. Number of patients with PD-L1 expression at nivolumab initiation

    PD-LI (Programmed death-ligand 1)

    Time frame: At baseline

  15. Number of patients with mutations at nivolumab initiation

    Time frame: At baseline

  16. Distribution of concomitant diseases at nivolumab initiation

    Time frame: At baseline

  17. Number of patients with corticosteroids treatment at nivolumab initiation

    Time frame: At baseline

  18. (OS) Overall Survival

    Time from index date (treatment with nivolumab) until date of death due to any cause

    Time frame: Up to 3 years

Secondary outcomes

  1. Overall Survival after initiation of nivolumab

    Time frame: Up to 2 years

  2. Distribution of nivolumab adverse drug reaction

    Time frame: At 3 years after nivolumab initiation

  3. Progression Free Survival (PFS)

    PFS measured by time since index date (initial treatment with nivolumab) to either the first disease progression date or last known tumor assessment date, or death due to any cause, whichever occurs first as assessed by RECIST 1.1

    Time frame: Up to 3 years after nivolumab initiation

  4. Objective Response Rate (ORR)

    ORR is measured by the sum of partial responses plus complete responses as assessed by (RECIST 1.1) Response Evaluation Criteria In Solid Tumors

    Time frame: Up to 3 years after nivolumab initiation

  5. Quality of Life (QoL)

    Time frame: Baseline to 3 years after nivolumab initiation

  6. Distribution of patient management treatment patterns

    Time frame: Baseline to 3 years

  7. Mean weight change in kilogram from baseline

    Time frame: Baseline up to 3 years

  8. Mean ECOG PS change from baseline

    Time frame: Baseline up to 3 years

  9. Distribution of patients with new metastasis

    Time frame: Up to 3 years

  10. Distribution of patients with progression of pre-existing sites

    Time frame: Up to 3 years

07

Study locations

1 site
  • Local Institution
    Fontaine Les Dijon, 21121, France
08

References and documents

Publications

  • Barlesi F, Dixmier A, Debieuvre D, Raspaud C, Auliac JB, Benoit N, Bombaron P, Moro-Sibilot D, Audigier-Valette C, Asselain B, Egenod T, Rabeau A, Fayette J, Sanchez ML, Labourey JL, Westeel V, Lamoureux P, Cotte FE, Allan V, Daumont M, Dumanoir J, Reynaud D, Calvet CY, Ozan N, Perol M. Effectiveness and safety of nivolumab in the treatment of lung cancer patients in France: preliminary results from the real-world EVIDENS study. Oncoimmunology. 2020 Apr 12;9(1):1744898. doi: 10.1080/2162402X.2020.1744898. PubMed 33457089 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2016 to primary completion in Dec 2020, 50 months.

Of 90 industry-sponsored observational studies under Lung Neoplasms, half reached primary completion within 48 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 58. This study's 50 months is close to that.

Counting every sponsor, half of 682 studies reached it within 57 months; a quarter within 25 and three quarters within 135.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 19, 2017
First posted
Dec 26, 2017
StartActual
Oct 1, 2016
Primary completionActual
Dec 23, 2020
CompletionActual
Dec 23, 2020
Last update
May 25, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 25, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03382496
Responsible party
Sponsor
First posted
Dec 26, 2017
Start date
Oct 1, 2016
Primary completion
Dec 23, 2020
Completion
Dec 23, 2020
Last update
May 25, 2022

Study contacts

Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion